Compositions and Methods for Non-Surgical Treatment of Ptosis
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
1 - 40 . (canceled)
41 . A pharmaceutical composition formulated for topical ophthalmic administration comprising about 0.05 to 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof.
42 . The pharmaceutical composition of claim 41 , comprising about 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof.
43 . The pharmaceutical composition of claim 41 , wherein the oxymetazoline or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt of oxymetazoline.
44 . The pharmaceutical composition of claim 43 , wherein the pharmaceutically acceptable salt of oxymetazoline is oxymetazoline hydrochloride.
45 . The pharmaceutical composition of claim 44 , comprising about 0.1 weight percent oxymetazoline hydrochloride based on the oxymetazoline component alone.
46 . A squeeze bottle or dropper comprising the pharmaceutical composition of claim 41 , wherein the squeeze bottle or dropper is capable of delivering a single drop with a volume of about 0.1 to 0.35 mL.
47 . The squeeze bottle or dropper of claim 46 , comprising about 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof.
48 . A kit comprising the squeeze bottle or dropper of claim 45 and instructional materials directing administration of the pharmaceutical composition in a method for treating ptosis in a human patient.
49 . The kit of claim 48 , comprising about 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof.
50 . The kit of claim 46 , wherein the instructional materials directing administration of the pharmaceutical formulation as a single drop.